Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$47.62 USD

47.62
1,462,070

-1.35 (-2.76%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $47.70 +0.08 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

5 Reasons to Invest in Novo Nordisk (NVO) Stock Right Now

by Zacks Equity Research

Let's take a look at few factors that help in determining if Novo Nordisk (NVO) will be a good investment in 2018.

    TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise

    by Zacks Equity Research

    TherapeuticsMD (TXMD) announces submission of NDA to the FDA seeking approval of TX-001HR to treat vasomotor symptoms in post-menopausal women.

      What Drives Catalyst Pharmaceuticals Above 250% This Year?

      by Zacks Equity Research

      We take a look at the factors that drive phenomenal growth in Catalyst Pharmaceuticals' (CPRX) share price in 2017.

        Actinium Posts Positive DMC View on Lomab-B Phase III Trial

        by Zacks Equity Research

        Independent Data Monitoring Committee endorses evaluation of Actinium's (ATNM) lead pipeline candidate, Iomab-B, for a pivotal phase III SIERRA study.

          Horizon Pharma Gets FDA Nod for Procysbi Label Expansion

          by Zacks Equity Research

          The FDA approves label expansion for Horizon Pharma's (HZNP) Procysbi (cysteamine bitartrate) delayed-release capsules for children aged a year and older with nephropathic cystinosis.

            Insys' Cannabidiol Gets Fast Track Designation in the U.S.

            by Zacks Equity Research

            The FDA grants a fast track status to Insys' (INSY) cannabidiol oral solution for Prader-Willi syndrome. The company also plans to move the candidate into clinical development in first-quarter 2018.

              Agios (AGIO) Files NDA for Leukemia Candidate in the U.S.

              by Zacks Equity Research

              Agios (AGIO) submits new drug application to the FDA for ivosidenib for relapsed or refractory acute myeloid leukemia and IDH1 mutation. The company has also filed request for a priority review.

                Why is Corcept's Stock Up More Than 150% So Far This Year?

                by Zacks Equity Research

                We take a look at the factors that drove the phenomenal growth in share price of Corcept (CORT) in 2017.

                  Alexion's (ALXN) Soliris Label Expansion Approved in Japan

                  by Zacks Equity Research

                  Alexion's (ALXN) announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan approved the label expansion of Soliris for the treatment of patients with generalized myasthenia gravis (gMG).

                    Merck's Diabetes Drugs Get FDA Nod as Adjunct Therapies

                    by Zacks Equity Research

                    Merck's (MRK) three diabetes drugs get FDA approval as adjunct treatment to diet and exercise to improve glycemic control in patients with diabetes mellitus.

                      BioMarin's (BMRN) Pegvaliase Review Period Extended by FDA

                      by Zacks Equity Research

                      BioMarin (BMRN) extended the review period of its biologics license application (BLA) for pegvaliase by three months to May 25, 2018.

                        Portola's (PTLA) AndexXa BLA Review Period Extended by FDA

                        by Zacks Equity Research

                        The FDA extends the review period of Portola's (PTLA) biologics license application for AndexXa by 90 days. Its response is now deferred to May 4, 2018 instead of the earlier Feb 3 deadline.

                          Strength Seen in Corcept Therapeutics (CORT): Stock Soars 10.8%

                          by Zacks Equity Research

                          Corcept Therapeutics (CORT) was a big mover last session, as the company saw its shares rise more than 10% on the day amid huge volumes.

                            Jazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder

                            by Zacks Equity Research

                            Jazz submits a new drug application to the FDA for JZP-110 (solriamfetol) for treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.

                              Allergan/Paratek's Acne Candidate NDA Filing Accepted by FDA

                              by Zacks Equity Research

                              Allergan (AGN) and partner Paratek announces that its new drug application for Seysara has been accepted for review by the FDA for moderate to severe acne vulgaris.

                                Achillion's Renal Disease Candidate Gets Orphan Drug Status

                                by Zacks Equity Research

                                Achillion Pharmaceuticals' (ACHN) factor D inhibitor, ACH-4471, gets orphan drug designation for treating C3G, a renal disease.

                                  Regeneron in Strategic Immuno-Oncology Collaboration With ISA

                                  by Zacks Equity Research

                                  Regeneron Pharmaceuticals (REGN) and ISA Pharmaceuticals inked an agreement to advance ISA101 in combination with cemiplimab.

                                    Alnylam/Sanofi Submit MAA in Europe for RNAi Candidate

                                    by Zacks Equity Research

                                    Alnylam (ALNY) and partner Sanofi have submitted a Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment adults with hereditary ATTR amyloidosis with polyneuropathy.

                                      Novartis (NVS) Oncology Head Strigini to Step Down by Dec. 31

                                      by Zacks Equity Research

                                      Novartis (NVS) is at a transitional stage as the CEO of its oncology segment will step down by the end of year. The company's CEO is also going to step next year.

                                        Radius Health to Get Third Day-180 List of Outstanding Issues

                                        by Zacks Equity Research

                                        Radius Health (RDUS) will get a third Day-180 List of Outstanding Issues from the CHMP for its marketing authorisation application of abaloparatide-SC leading to a further delay in tentative approval.

                                          Spectrum Pharma Dismisses CEO, Makes Leadership Changes

                                          by Zacks Equity Research

                                          Spectrum Pharma (SPPI) terminates Rajesh Shrotriya and appoints its present COO, Joseph Turgeon, as the new CEO.

                                            Shire's New Formulation of Oncaspar Gets Approval in Europe

                                            by Zacks Equity Research

                                            Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar receives approval from the European Commission.

                                              Regeneron, Sanofi Report Positive Top Line Skin Cancer Data

                                              by Zacks Equity Research

                                              Regeneron (REGN) and partner Sanofi announced positive top-line results from a pivotal phase II study of skin cancer candidate cemiplimab.

                                                Allergan Inks Deal to Buy Texas-Based Repros Therapeutics

                                                by Zacks Equity Research

                                                Allergan (AGN) signs a definitive contract to acquire Texas-based Repros Therapeutics, which is focused on developing new drugs to treat hormonal and reproductive system disorders.

                                                  Glaxo's Nucala Label Expansion Application Gets FDA Approval

                                                  by Zacks Equity Research

                                                  GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.